Coltuximab ravtansine

N/A

Report date: 2024/02/05 13:57:55

Base Information

Drug NameColtuximab ravtansine
Drug Alias NamehuB4-DM4SAR-3419
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > SPDB linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > DM4 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionTubulin polymerisation inhibitorsAnti-CD19
TargetsB-lymphocyte antigen CD19Tubulin
Therapy Area/IndicationsLymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinLymphoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumUnited States +[12] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesImmunogen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSanofi
Active IndicationsN/A
Inactive IndicationsLymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinLymphoma +[4] 

Other Information

ATC CodeN/A
Related LinksWikipedia